Edition:
United States

TESARO Inc (TSRO.OQ)

TSRO.OQ on NASDAQ Stock Exchange Global Select Market

51.76USD
25 May 2018
Change (% chg)

$3.18 (+6.55%)
Prev Close
$48.58
Open
$48.50
Day's High
$51.79
Day's Low
$48.32
Volume
401,229
Avg. Vol
358,752
52-wk High
$168.91
52-wk Low
$44.76

Chart for

About

TESARO, Inc. is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.... (more)

Overall

Beta: 1.24
Market Cap(Mil.): $2,837.67
Shares Outstanding(Mil.): 54.82
Dividend: --
Yield (%): --

Financials

  TSRO.OQ Industry Sector
P/E (TTM): -- 238.69 33.30
EPS (TTM): -9.61 -- --
ROI: -85.61 -7.54 13.04
ROE: -165.54 -10.33 14.90

BRIEF-Tesaro Reports Q1 Loss Per Share Of $2.98

* Q1 EARNINGS PER SHARE VIEW $-2.69 -- THOMSON REUTERS I/B/E/S

May 03 2018

BRIEF-Tesaro Announces Positive Top-Line Results From Quadra Trial Of Zejula

* TESARO ANNOUNCES POSITIVE TOP-LINE RESULTS FROM QUADRA TRIAL OF ZEJULA

Apr 24 2018

BRIEF-Tesaro Summarizes TSR-042 Clinical Data Presented At AACR

* TESARO INC - EXPECT TO COMPLETE ENROLLMENT IN MSI-H ENDOMETRIAL COHORT OF GARNET TRIAL BY END OF YEAR Source text for Eikon: Further company coverage:

Apr 16 2018

BRIEF-Tesaro And Medison Enter Into Exclusive Distribution Agreement To Commercialize Zejula In Israel

* TESARO AND MEDISON ENTER INTO EXCLUSIVE DISTRIBUTION AGREEMENT TO COMMERCIALIZE ZEJULA® IN ISRAEL

Apr 11 2018

BRIEF-Tesaro Says TOPACIO Data Demonstrates Compelling Clinical Activity Of Zejula In Patients With Type Of Ovarian Cancer

* DATA FROM TOPACIO TRIAL REPORTED AT SGO DEMONSTRATES COMPELLING CLINICAL ACTIVITY OF ZEJULA IN COMBINATION WITH AN ANTI-PD-1 ANTIBODY IN PATIENTS WITH PLATINUM RESISTANT/REFRACTORY OVARIAN CANCER

Mar 26 2018

BRIEF-Tesaro Inc Q4 Loss Per Share $3.35

* TESARO ANNOUNCES FOURTH-QUARTER AND FULL-YEAR 2017 OPERATING RESULTS

Feb 27 2018

BRIEF-Tesaro collaborates with Roche to evaluate their combination treatment for bladder cancer

* TESARO ANNOUNCES COLLABORATION TO EVALUATE COMBINATION OF ZEJULA® (NIRAPARIB) AND ANTI-PD-L1 CANCER IMMUNOTHERAPY IN METASTATIC BLADDER CANCER

Feb 26 2018

BRIEF-Tesaro Says Anaphylactic Shock, Other Hypersensitivity Reactions Reported For Varubi Injectable Emulsion

* TESARO ANNOUNCES UPDATES TO THE U.S. PRESCRIBING INFORMATION FOR VARUBI (ROLAPITANT) INJECTABLE EMULSION

Jan 12 2018

Exclusive: U.S. cancer drugmaker Ignyta in advanced sale talks - sources

Ignyta Inc is in advanced talks to sell itself, people familiar with the matter said on Thursday, just three years after the U.S. cancer drugmaker became a public company focused on precision drugs and diagnostics.

Dec 21 2017

Earnings vs. Estimates